Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
10th Anniversary of Biomedicines—Advances in Gastrointestinal Cancers Diagnostics and Therapeutics
share announcement

10th Anniversary of Biomedicines—Advances in Gastrointestinal Cancers Diagnostics and Therapeutics

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (15 November 2022) | Viewed by 4978

Special Issue Editors

Prof. Dr. Antonio Biondi

grade E-Mail Website
Guest Editor
Department of General Surgery and Surgical - Medical Specialties, University of Catania, Catania, Italy
Interests: colorectal cancer; general surgery; screening; biomarkers; quality of life; liquid biopsy; microbiota
Special Issues, Collections and Topics in MDPI journals
Dr. Marco Vacante

E-Mail Website
Guest Editor
Department of General Surgery and Surgical - Medical Specialties, University of Catania, Catania, Italy
Interests: colorectal cancer; elderly care; nutrition; quality of life; liquid biopsy; cancer biomarkers; microbiota
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

The year 2023 marks the 10th anniversary of Biomedicines, a peer-reviewed open access journal in the biomedical field. So far, Biomedicines has published more than 2700 papers from more than 17,000 authors. We appreciate each author, reviewer, and academic editor whose support has brought us to where we are today. To celebrate this significant milestone, we aim to publish a Special Issue entitled 10th Anniversary of Biomedicines—Advances in Gastrointestinal Cancers Diagnostics and Therapeutics.

This Special Issue focuses on recent advances in diagnostics and therapeutics for gastrointestinal (GI) cancer patients. GI cancers represent an increasing medical and economic burden worldwide. Esophageal, gastric, and colorectal cancers might be associated with modifiable and preventable lifestyle habits. Screening programs and earlier diagnosis and treatment are increasingly involving medical and surgical facilities, endoscopic expertise, and investment of financial resources. We invite the submission of research articles that will improve our knowledge on these topics. This Special Issue will publish original research and review articles. 

Prof. Dr. Antonio Biondi
Dr. Marco Vacante
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • gastric cancer
  • esophageal cancer
  • biomarkers
  • microbiota
  • liquid biopsy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 3336 KiB  
Article
Identification of a Novel Protein-Based Prognostic Model in Gastric Cancers
by Zhijuan Xiong, Chutian Xing, Ping Zhang, Yunlian Diao, Chenxi Guang, Ying Ying and Wei Zhang
Biomedicines 2023, 11(3), 983; https://doi.org/10.3390/biomedicines11030983 - 22 Mar 2023
Viewed by 1383
Abstract
Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide. However, there are still no reliable biomarkers for the prognosis of this disease. This study aims to construct a robust protein-based prognostic prediction model for GC patients. The protein expression data [...] Read more.
Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide. However, there are still no reliable biomarkers for the prognosis of this disease. This study aims to construct a robust protein-based prognostic prediction model for GC patients. The protein expression data and clinical information of GC patients were downloaded from the TCPA and TCGA databases, and the expressions of 218 proteins in 352 GC patients were analyzed using bioinformatics methods. Additionally, Kaplan–Meier (KM) survival analysis and univariate and multivariate Cox regression analysis were applied to screen the prognosis-related proteins for establishing the prognostic prediction risk model. Finally, five proteins, including NDRG1_pT346, SYK, P90RSK, TIGAR, and XBP1, were related to the risk prognosis of gastric cancer and were selected for model construction. Furthermore, a significant trend toward worse survival was found in the high-risk group (p = 1.495 × 10−7). The time-dependent ROC analysis indicated that the model had better specificity and sensitivity compared to the clinical features at 1, 2, and 3 years (AUC = 0.685, 0.673, and 0.665, respectively). Notably, the independent prognostic analysis results revealed that the model was an independent prognostic factor for GC patients. In conclusion, the robust protein-based model based on five proteins was established, and its potential benefits in the prognostic prediction of GC patients were demonstrated. Full article
(This article belongs to the Special Issue 10th Anniversary of Biomedicines—Advances in Gastrointestinal Cancers Diagnostics and Therapeutics)
►▼ Show Figures

Figure 1

15 pages, 2049 KiB  
Article
Exploratory Evaluation of Neopterin and Chitotriosidase as Potential Circulating Biomarkers for Colorectal Cancer
by Andra Ciocan, Răzvan A. Ciocan, Nadim Al Hajjar, Andreea M. Benea, Stanca L. Pandrea, Cristina S. Cătană, Cristina Drugan, Valentin C. Oprea, Dan S. Dîrzu and Sorana D. Bolboacă
Biomedicines 2023, 11(3), 894; https://doi.org/10.3390/biomedicines11030894 - 14 Mar 2023
Cited by 4 | Viewed by 1282
Abstract
Chronic inflammation is demonstrated to play a direct role in carcinogenesis. Our exploratory study aimed to assess the potential added value of two inflammation biomarkers, chitotriosidase and neopterin, in follow-up evaluation of patients with colorectal cancer (CRC). An observational exploratory study was conducted. [...] Read more.
Chronic inflammation is demonstrated to play a direct role in carcinogenesis. Our exploratory study aimed to assess the potential added value of two inflammation biomarkers, chitotriosidase and neopterin, in follow-up evaluation of patients with colorectal cancer (CRC). An observational exploratory study was conducted. Patients with CRC and matched controls (1:1, age, sex, and living environment) were evaluated. The patients with CRC (CRC group) and controls were assessed at baseline (before surgical intervention for patients with CRC). Patients with CRC were also evaluated at 1-year follow-up. Significantly more patients with blood group A (54.5% vs. 25.0%) and smokers (50.0% vs. 22.7%) were in the CRC group. The serum values of chitotriosidase and neopterin were higher in CRC patients than in controls, but only neopterin reached the conventional level of statistical significance (p-value = 0.015). The circulating chitotriosidase and neopterin values decreased significantly at 1-year follow-up (p-value < 0.0001). Patients with higher N- and M-stage showed statistically significant higher levels of chitotriosidase and neopterin at baseline and 1-year follow-up (p-values < 0.03). Circulating chitotriosidase levels also showed statistically significant differences regarding baseline and 1-year follow-up on patients with CRC and different differentiation grades (p-values < 0.02). The circulating levels of neopterin significantly decreased at 1-year follow-up, indicating its potential as a prognostic marker. The circulating values of chitotriosidase and neopterin exhibit significant differences in patients with than without recurrences. Our results support further evaluation of chitotriosidase and neopterin as prognostic markers in patients with CRC. Full article
(This article belongs to the Special Issue 10th Anniversary of Biomedicines—Advances in Gastrointestinal Cancers Diagnostics and Therapeutics)
►▼ Show Figures

Figure 1

17 pages, 44083 KiB  
Article
Characteristic Analysis of Featured Genes Associated with Cholangiocarcinoma Progression
by Qigu Yao, Wenyi Chen, Feiqiong Gao, Yuchen Wu, Lingling Zhou, Haoying Xu, Jong Yu, Xinli Zhu, Lan Wang, Lanjuan Li and Hongcui Cao
Biomedicines 2023, 11(3), 847; https://doi.org/10.3390/biomedicines11030847 - 10 Mar 2023
Viewed by 1777
Abstract
The noninvasive diagnosis of cholangiocarcinoma (CCA) is insufficiently accurate. Therefore, the discovery of new prognostic markers is vital for the understanding of the CCA mechanism and related treatment. The information on CCA patients in The Cancer Genome Atlas database was used for weighted [...] Read more.
The noninvasive diagnosis of cholangiocarcinoma (CCA) is insufficiently accurate. Therefore, the discovery of new prognostic markers is vital for the understanding of the CCA mechanism and related treatment. The information on CCA patients in The Cancer Genome Atlas database was used for weighted gene co-expression network analysis. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were applied to analyze the modules of interest. By using receiver operating characteristic (ROC) analysis to analyze the Human Protein Atlas (HPA), the featured genes were subsequently verified. In addition, clinical samples and GSE119336 cohort data were also collected for the validation of these hub genes. Using WGCNA, we identified 61 hub genes that regulated the progression and prognosis of CCA. Eight hub genes (VSNL1, TH, PCP4, IGDCC3, RAD51AP2, MUC2, BUB1, and BUB1B) were identified which exhibited significant interactions with the tumorigenic mechanism and prognosis of CCA. In addition, GO and KEGG clarified that the blue and magenta modules were involved with chromosome segregation, mitotic and oocyte meiosis, the cell cycle, and sister chromatid segregation. Four hub genes (VSNL1, PCP4, BUB1, and BUB1B) were also verified as featured genes of progression and prognosis by the GSE119336 cohort data and five human tissue samples. Full article
(This article belongs to the Special Issue 10th Anniversary of Biomedicines—Advances in Gastrointestinal Cancers Diagnostics and Therapeutics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop